Organization |
Field Name |
ID |
Required |
---|---|---|---|
KCR |
ALK Rearrangement |
34125 |
yes |
SEER |
ALK Rearrangement |
3938 |
yes |
Note 1 This SSDI is effective for diagnosis years 2021+
- For cases diagnosed 2018-2020, leave this SSDI blank
Note 2 Physician statement of ALK rearrangement for non-small cell carcinoma can be used to code this data item when no other information is available.
Note 3 ALK may be recorded for all histologies and stages; however, it is primarily performed for advanced non-small cell carcinomas. If information is not available, code 9.
Note 4 The absence or presence of ALK protein expression determines if the tumor will respond to treatment with a targeted inhibitor. ALK protein expression predicts the ALK rearrangement gene, which are more likely to respond to the targeted inhibitor treatment. The most common ALK rearrangements are
- EML4-ALK
- KIF5B-ALK
- TFG-ALK
- KLC1-ALK
Note 5 If ALK Rearrangement is positive and there is no mention of the specific rearrangement, code 4.
Note 6 If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy.
- If neoadjuvant therapy is given and there are no ALK results from pre-treatment specimens, report the findings from post-treatment specimens
Note 7 Code 9 when
- Insufficient amount of tissue available to perform test
- Test done and documented to be equivocal
- No microscopic confirmation of tumor
- ALK Rearrangement not ordered or not done, or unknown if ordered or done
Code |
Description |
---|---|
0 |
Normal |
1 |
Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK |
2 |
Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1 |
4 |
Rearrangement, NOS |
7 |
Test ordered, results not in chart |
8 |
Not applicable: Information not collected for this case |
9 |
Not documented in medical record |
<BLANK> |
N/A - Diagnosis year is prior to 2021 |